By Liz White, UT staffStrathclyde, Scotland-Biotechnology group AorTech International plc announced in late November that it one of its licensees has "gained FDA approval for a long-term implantable, life-sustaining device utilising its polymer technology, Elast-Eon." Elast-Eon is a biocompatible silicone/polyurethane material developed by scientists in Australia. This approval is the result of considerable effort over the past three years on the part of AorTech and its licensee partner," said AorTech ceo Frank Maguire. Commenting that this approval results from considerable effort over the past three years by AorTech and its licensee, Maguire went on to describe the approval as significant since "it validates the application of Elast-Eon in a high-demand, long-term implant with a well respected licensee." "I believe this approval will serve to accelerate the numerous other application programs AorTech has underway in a variety of medical device markets," the AorTech chief said. The approval is significant in the sense that it validates the application of Elast-Eon in a high-demand, long-term implant with a well respected licensee. I believe this approval will serve to accelerate the numerous other application programs AorTech has underway in a variety of medical device markets." Aortech recently announced progress in one potential use for Elast-Eon in breast implants, but the use here is obviously another application. This FDA approval follows the granting of a CE Mark in Europe for the same family of devices earlier this year, said the Scottish company.Aortech described the particular device market for this product as "large and characterised by robust growth." AorTech will receive a $150 000 milestone payment and said "royalty revenues are anticipated to commence with first human use in Q1 2006." AorTech has consequently entered an agreement with the licensee for the client to fund a scale up of its manufacturing operations-in Melbourne, Australia. This is currently underway and is anticipated to be completed in Q1 of 2006, "